Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer that is clinically defined as lacking estrogen and progesterone receptors, as well as being ERBB2 (HER-2) negative. Without specific therapeutic targets, TNBC carries a worse prognosis than other types of breast cancer in th...
Main Authors: | David J. Hiller, Quyen D. Chu |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | International Journal of Breast Cancer |
Online Access: | http://dx.doi.org/10.1155/2012/829315 |
Similar Items
-
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
by: Ohmoto A, et al.
Published: (2017-10-01) -
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma
by: Jerred P. Pletcher, et al.
Published: (2021-07-01) -
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
by: Joseph A. De Soto, Xianyan Wang, Yohei Tominaga, Rui-Hong Wang, Liu Cao, Wenhui Qiao, Cuiling Li, Xiaoling Xu, Amanda P. Skoumbourdis, Sheila A. Prindiville, Craig J. Thomas, Chu-Xia Deng
Published: (2006-01-01) -
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
by: Maurie Markman
Published: (2018-01-01) -
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020-03-01)